期刊文献+

胸水肿瘤标志物检测对肺癌所致胸腔积液的诊断价值 被引量:6

Detection of Pleural Effusion Tumor Markers in the Diagnosis of Pleural Effusion Caused by Lung Cancer
下载PDF
导出
摘要 目的研究肺癌所致胸腔积液临床诊断中进行胸水肿瘤标志物检测的价值。方法方便选择2015年1月—2018年1月该院肺癌所致胸腔积液患者50例,全部患者均接受胸水肿瘤标志物癌胚抗原(CEA)、癌抗原125(CA125)、神经原特异性烯醇化酶(NSE)、细胞角蛋白19片段(CYFRA 21-1)4项检测,分析检测结果。结果肺腺癌患者CEA、CA125为(407.93±111.12)μg/L、(1 144.45±1 360.42)U/mL,高于肺鳞癌(146.36±68.49)μg/L、(562.19±118.74)U/mL以及肺小细胞癌(204.63±81.59)μg/L、(462.79±78.45)U/mL,肺鳞癌CYFRA 21-1(86.59±34.22)ng/mL高于肺腺癌(27.15±13.05)ng/mL、肺小细胞癌(10.48±5.30)ng/mL,肺小细胞癌NSE(127.89±50.01)ug/mL高于肺腺癌(27.36±10.63)ug/mL、肺鳞癌(9.59±3.62)ug/mL;胸腔积液标本CEA、CA125、CYFRA21-1、NSE指标结果 (274.60±357.45)μg/L、(784.18±115.40)U/mL、(40.05±15.79)ng/mL、(49.90±20.46)μg/mL,高于血清(41.18±15.26)μg/L、(125.78±68.29)U/mL、(11.22±5.16)ng/mL、(24.75±3.18)μg/mL(t=96.321 4、80.157 2、26.301 8、31.027 5,P<0.000)。结论胸水肿瘤标志物4项检测对肺癌所致胸腔积液的诊断价值优于血清标志物,通过胸水肿瘤标志物检测能够协助临床区分癌症具体类型,实现胸腔积液的更准确诊断。 Objective This paper tries to study the value of pleural effusion tumor markers in clinical diagnosis of pleural effusion caused by lung cancer. Methods 50 patients with pleural effusion caused by lung cancer in this hospital from January 2015 to January 2018 were selected conveniently. All patients received CEA, CA 125, neurogenic specific encephalitis markers. The four tests of alcoholase(NSE) and cytokeratin 19 fragment(CYFRA 21-1) were performed and the results were ana lyzed. Results The CEA and CA125 in patients with lung adenocarcinoma were(407.93±111.12)μg/L,(1 144.45±1 360.42)U/mL,higher than those in squamous cell carcinoma(146.36±68.49) μg/L,(562.19±118.74)U/mL, and lung small cell carcinoma(204.63±81.59)μg/L,(462.79±78.45)U/mL, lung squamous cell carcinoma CYFRA 21-1(86.59±34.22)ng/mL was higher than lung adenocarcinoma(27.15±13.05)ng/mL, small cell lung cancer(10.48±5.30)ng/mL, NSE(127.89±50.01)μg/mL was higher than that of lung adenocarcinoma(27.36±10.63) ug/mL, lung squamous cell carcinoma(9.59±3.62)μg/mL. Pleural effusion specimens CEA, CA125, CYFRA21-1, NSE index results(274.60±357.45)μg/L,(784.18±115.40)U/mL,(40.05±15.79)ng/mL,(49.90±20.46)μg/mL, higher than serum(41.18±15.26)μg/L,(125.78±68.29)U/mL,(11.22±5.16)ng/mL,(24.75 ±3.18)μg/mL(t=96.321 4, 80.157 2, 26.301 8, 31.027 5, P〈0.000). Conclusion Four items of pleural effusion tumor markers are superior to serum markers in the diagnosis of pleural effusions caused by lung cancer. The detection of pleural effusion tumor markers can help distinguish clinical cancer types and achieve more accurate diagnosis of pleural effusions.
作者 黄河 李肇暖 郑惠兰 HUANG He;LI Zhao-nuan;ZHENG Hui-lan(Department Laboratory,the Second Hospital of Sanming City,Sanming,Fujian Province,366000 Chin)
出处 《中外医疗》 2018年第18期169-171,共3页 China & Foreign Medical Treatment
关键词 肺癌 胸腔积液 胸水 肿瘤标志物 检测 Lung cancer Pleural effusion Pleural fluid Tumor markers Detection
  • 相关文献

参考文献8

二级参考文献60

  • 1边清泉,杨振萍.红车轴草中刺芒柄花素的微波法提取工艺[J].化学研究与应用,2005,17(3):431-432. 被引量:7
  • 2刘运秋,于立群,林江涛.检测肿瘤标志物ProGRP、NSE、CYFRA21-1、CEA对胸腔积液鉴别诊断价值的研究[J].中国肺癌杂志,2006,9(3):273-276. 被引量:18
  • 3Liu L, Liu B, Zhu LL, et al. Clinical significance of CYFRA21-1, Sec-Ag and telomerase activity in serum and pleural effusion of patients with squamous-ceU lung cancer [J].Bioanalysis, 2012, 4 (19) : 2367-2374. 被引量:1
  • 4Lee DS, Kim SJ, Kang JH, et al. Serum Carcinoembryonic Antigen Levels and the Risk of Whole-body Metastatic Potential in Advanced Non-small Cell Lung Cancer [J]. J Cancer, 2014, 5 (8) : 663-669. 被引量:1
  • 5Yang ZM, Ding XP, Pen L, et al. Analysis of CEA expressionand EGFR mutation status in non-small cell lung cancers [J]. Asian Pac J Cancer Prey, 2014,15 (8) :3451-3455. 被引量:1
  • 6Qin HF, Qu LL, Liu H, et al. Serum CEA level change and its significance before and after Gefitinib therapy on patients with advanced non-small cell lung cancer [J]. Asian Pac J Cancer Prey, 2013,14(7) :4205-4208. 被引量:1
  • 7Ma S, Shen L, Qian N, et al. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited [J]. Cancer Biomark, 2011-2012(3-4) : 155-162. 被引量:1
  • 8Fiala O, Pesek M, Finek J, et al. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib [J]. Anticancer Res, 2014,34(6) : 3205-3210. 被引量:1
  • 9Jung M, Kim SH, Hang S, et al. Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib [J ]. Yonsei Med J, 2012,53 (5) : 931-939. 被引量:1
  • 10Yu D, Du K, Liu T, et al. Prognostic value of tumor markers, NSE,CA125 and SCC,in operable NSCLC Patients [J]. Int J Mol Sci, 2013,14(6) : 11145-11156. 被引量:1

共引文献91

同被引文献64

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部